Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel

Biomaterials

Volumn 30, Issue 19, 2009, Pages 3297-3306

  Feng, Si Shen ^a   Mei, Lin ^a   Anitha, Panneerselvan ^a   Gan, Chee Wee ^a   Zhou, Wenyou ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticancer drugs; Biodegradable polymers; Cancer nanotechnology; Drug delivery device; Medical clay; Oral chemotherapy

Indexed keywords

ANTICANCER DRUGS; CANCER NANOTECHNOLOGY; DRUG DELIVERY DEVICE; MEDICAL CLAY; ORAL CHEMOTHERAPY;

ACIDS; ADSORPTION; BIOCHEMISTRY; BIODEGRADABLE POLYMERS; CHEMOTHERAPY; CLAY MINERALS; DRUG INTERACTIONS; DRUG PRODUCTS; EMULSIFICATION; ENCAPSULATION; ESTERS; ETHYLENE GLYCOL; FUNCTIONAL POLYMERS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; SILICATE MINERALS; SODIUM COMPOUNDS; SURFACE CHEMISTRY; THERMOPLASTICS;

CONTROLLED DRUG DELIVERY;

ALPHA TOCOPHEROL DERIVATIVE; COPOLYMER; COUMARIN DERIVATIVE; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; DOCETAXEL; MONTMORILLONITE; NANOCARRIER; POLYGLACTIN; POLYLACTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL ADHESION; CELL TRANSPORT; CELL VIABILITY; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SOLVENT EXTRACTION; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BENTONITE; CELL LINE; COUMARINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG THERAPY; HUMANS; LACTIC ACID; MALE; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; THIAZOLES; VITAMIN E;

RATTUS;

EID: 67349198099     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.02.045     Document Type: Article

References (42)

1. Feng S.S., and Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science 58 18 (2003) 4087-4114
2. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. American Journal of Health-System Pharmacy 64 (2007) S4-S7
3. Gelderblom H., Verweij J., Nooter K., and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer 37 13 (2001) 1590-1598
4. Ten Tije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clinical Pharmacokinetics 42 7 (2003) 665-685
5. Eiseman J.L., Eddington N.D., Leslie J., Macauley C., Sentz D.L., Zuhowski M., et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F-1 mice. Cancer Chemotherapy and Pharmacology 34 6 (1994) 465-471
6. Fujita H., Okamoto M., Takao A., Mase H., and Kojima H. Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level. Gan To Kagaku Ryoho 21 5 (1994) 653-658
7. Terwogt J.M.M., Beijnen J.H., Huinink W.W.T., Rosing H., and Schellens J.H.M. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352 9124 (1998) 285
8. Malingre M.M., Beijnen J.H., and Schellens J.H.M. Oral delivery of taxanes. Investigational New Drugs 19 2 (2001) 155-162
9. Malingre M.M., Richel D.J., Beijnen J.H., Rosing H., Koopman F.J., Huinink W., et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of Docetaxel. Journal of Clinical Oncology 19 4 (2001) 1160-1166
10. Malingre M.M., Beijnen J.H., Rosing H., Koopman F.J., van Tellingen O., Duchin K., et al. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anti-Cancer Drugs 12 4 (2001) 351-358
11. Malingre M.M., Schellens J.H.M., van Tellingen O., Rosing H., Koopman F.J., Duchin K., et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anti-Cancer Drugs 11 10 (2000) 813-820
12. Malingre M.M., Terwogt J.M.M., Beijnen J.H., Rosing H., Koopman F.J., van Tellingen O., et al. Phase I and pharmacokinetic study of oral paclitaxel. Journal of Clinical Oncology 18 12 (2000) 2468-2475
13. DeMario M.D., and Ratain M.J. Oral chemotherapy: rationale and future directions. Journal of Clinical Oncology 16 7 (1998) 2557-2567
14. Feng S.S. SnapShot: nanoparticles of biodegradable polymers for cancer treatment. Biomaterials 29 30 (2008) 4146-4147
15. Feng S.S. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?. Nanomedicine 1 3 (2006) 297-309
16. Feng S.S. Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Review of Medical Devices 1 1 (2004) 115-125
17. Wawrezinieck A., Pean J.M., Wuthrich P., and Benoit J.P. Oral bioavailability and drug/carrier particulate systems. M S-Medicine Sciences 24 6-7 (2008) 659-664
18. Dong Y.C., and Feng S.S. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26 30 (2005) 6068-6076
19. Pamujula S., Graves R.A., Freeman T., Srinivasan V., Bostanian L.A., Kishore V., et al. Oral delivery of spray dried PLGA/amifostine nanoparticles. Journal of Pharmacy and Pharmacology 56 9 (2004) 1119-1125
20. Mu L., and Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol (R)): PLGA nanoparticles containing vitamin E TPGS. Journal of Controlled Release 86 1 (2003) 33-48
21. Bogman K., Zysset Y., Degen L., Hopfgartner G., Gutmann H., Alsenz J., et al. P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clinical Pharmacology & Therapeutics 77 1 (2005) 24-32
22. Fischer J., Harkin K., and Freeman L. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine A in healthy dogs. Veterinary Therapeutics 3 4 (2002) 465-473
23. Prasad Y.V.R., Puthli S.P., Eaimtrakarn S., Ishida M., Yoshikawa Y., Shibata N., et al. Enhanced intestinal absorption of vancomycin with labrasol and d-alpha-tocopheryl PEG 1000 succinate in rats. International Journal of Pharmaceutics 250 1 (2003) 181-190
24. Zhang Z.P., and Feng S.S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27 21 (2006) 4025-4033
25. Zhang Z.P., and Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27 2 (2006) 262-270
26. Zhang Z.P., Lee S.H., Gan C.W., and Feng S.S. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharmaceutical Research 25 8 (2008) 1925-1935
27. Dobrozsi D. Oral liquid mucoadhesive compositions. US Patent Appl. No.: 10/021,327; 2001.
28. Lin F.H., Lee Y.H., Jian C.H., Wong J.M., Shieh M.J., and Wang C.Y. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials 23 9 (2002) 1981-1987
29. Lee Y., Kuo T., Chen B., Feng Y., Wen Y., Lin W., et al. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model. Biomedical Engineering Applications, Basis and Communications 17 2 (2005) 12-18
30. Jones S. Head-to-head: Docetaxel challenges paclitaxel. EJC Supplements 4 4 (2006) 4-8
31. Jones S.E., Erban J., Overmoyer B., Budd G.T., Hutchins L., Lower E., et al. Randomized phase III study of Docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology 23 24 (2005) 5542-5551
32. Mu L., and Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol(R)). Journal of Controlled Release 80 1-3 (2002) 129-144
33. Norris D.A., Puri N., and Sinko P.J. The effect of physical barriers and properties on the oral absorption of particulates. Advanced Drug Delivery Reviews 34 2-3 (1998) 135-154
34. Florence A.T. Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discovery Today Technologies 2 1 (2005) 75-81
35. Win K.Y., and Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26 15 (2005) 2713-2722
36. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysics Research Communications 175 3 (1991) 880-885
37. Artursson P., Palm K., and Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Advanced Drug Delivery Reviews 46 1-3 (2001) 27-43
38. Nabholtz J.M., Tonkin K., Smylie M., Au H.J., Lindsay M.A., and Mackey J. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?. Expert Opinion on Pharmacotherapy 1 2 (2000) 187-206
39. Traber M.G., Thellman C.A., Rindler M.J., and Kayden H.J. Uptake of intact TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) a water-miscible form of vitamin E by human cells in vitro. American Journal of Clinical Nutrition 48 3 (1988) 605-611
40. Varma M.V.S., and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. European Journal of Pharmaceutical Sciences 25 4-5 (2005) 445-453
41. Lavie S., and Stotzky G. Adhesion of the clay minerals montmorillonite, kaolinite, and attapulgite reduces respiration of Histoplasma capsulatum. Applied and Environmental Microbiology 51 1 (1986) 65-73
42. 3 nanoparticles on cells cultured on ethylene vinyl acetate substrates and fibers. Biomaterials 30 1 (2009) 8-18